ST 1830
Alternative Names: ST-1830Latest Information Update: 15 Jan 2024
At a glance
- Originator Beijing Scitech-Mq Pharmaceuticals
- Class Anti-infectives; Antipsoriatics; Skin disorder therapies; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alopecia; Eczema; Pneumonia; Psoriasis; Sepsis; Vitiligo
Most Recent Events
- 11 Dec 2023 Preclinical trials in Alopecia in China (Parenteral) prior to December 2023 (Beijing Scitech-Mq Pharmaceuticals pipeline, December 2023)
- 11 Dec 2023 Preclinical trials in Eczema in China (Parenteral) prior to December 2023 (Beijing Scitech-Mq Pharmaceuticals pipeline, December 2023)
- 11 Dec 2023 Preclinical trials in Pneumonia in China (PO) prior to December 2023 (Beijing Scitech-Mq Pharmaceuticals pipeline, December 2023)